TABLE 1.
Pyro-RT-PCR and sequencing primers designed in the present study
Primer purpose and primer | Sequence | Target gene or residue(s) |
---|---|---|
Pyro-RT-PCR | ||
H1N1pdm-M2-F670 | 5′-AGCTCCAGTGCTGGTCTGAAAG-3′ | H1N1pdm-M2 |
H1N1pdm-M2-R900-biot | 5′-GACTCAGGCACTCCTTCCGTAGAA-3′ | |
H1N1pdm-N1-F256 | 5′-GCSGGCAATTCCTCTCTYTG-3′ | H1N1pdm-N1 fragment A |
H1N1pdm-N1-R730-biot | 5′-CGGTCATTACAGTAAARCAHGAACC-3′ | |
H1N1pdm-N1-F524 | 5′-ARTCAGTYGCTTGGTCAGCAAG-3′ | H1N1pdm-N1 fragment B |
H1N1pdm-N1-R908-biot | 5′-CAYGGTCGATTCGARSCATG-3′ | |
H1N1pdm-N1-F780 | 5′-GGGGAAGATTGTYAAATCAGTYGA-3′ | H1N1pdm-N1 fragment Ca |
H1N1pdm-N1-R1273-biot | 5′-CWACCCAGAARCAAGGYCTTATG-3′ | |
Pyrosequencing | ||
H1N1pdm-N1-F292 | 5′-GCTATATACAGTAAAGAC-3′ | V106b,c |
H1N1pdm-N1-F325 | 5′-GGTTCYAARGGGGA-3′ | V116, I117, E119c |
H1N1pdm-N1-F386 | 5′-GCAGAACCTTYTTCYTG-3′ | Q136c |
H1N1pdm-N1-F427 | 5′-AARCATTCCAATGGAAC-3′ | K150, D151c |
H1N1pdm-N1-F568 | 5′-TGG CTA ACA AT-3′ | D198c |
H1N1pdm-N1-F647 | 5′-TCAAGAGTTGGAGAAACA-3′ | I222c |
H1N1pdm-N1-F723 | 5′-AATGACYGATGGMCC-3′ | N247b,c |
H1N1pdm-N1-F804 | 5′-GYTGAATGCMCCTAATT-3′ | H274c |
H1N1pdm-N1-F864 | 5′-CACRTGTGTKTGCAG-3′ | N294c |
H1N1pdm-M2-F747 | 5′-GCGATTCAAGTGATCC-3′ | L26, V27, A30, S31, G34d |
H1N1pdm-M2-F801 | 5′-TGA TAT TGT GGA-3′ | L43d |
Set of primers published in 2009 by the CDC (8).
Residues are used for NA variant signatures and not antiviral resistance markers.
NA target residue(s).
M2 target residue(s).